bluebird bio, Inc. (0HOH.L)
USD 8.02
(1.01%)
USD 8.02
(1.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 424.62 Million USD | 18.43% |
| 2022 | 358.55 Million USD | 63.34% |
| 2021 | 219.51 Million USD | -48.49% |
| 2020 | 426.19 Million USD | -3.67% |
| 2019 | 442.43 Million USD | 23.66% |
| 2018 | 357.77 Million USD | 29.1% |
| 2017 | 277.13 Million USD | 11.44% |
| 2016 | 248.68 Million USD | 63.78% |
| 2015 | 151.84 Million USD | 131.88% |
| 2014 | 65.48 Million USD | -9.96% |
| 2013 | 72.72 Million USD | -41.85% |
| 2012 | 125.06 Million USD | 44.38% |
| 2011 | 86.62 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 500.43 Million USD | 17.85% |
| 2024 Q2 | 492.21 Million USD | -1.64% |
| 2023 Q4 | 424.62 Million USD | 8.58% |
| 2023 Q3 | 391.07 Million USD | 4.46% |
| 2023 Q2 | 374.37 Million USD | 10.76% |
| 2023 Q1 | 337.99 Million USD | -5.73% |
| 2023 FY | 424.62 Million USD | 18.43% |
| 2022 Q4 | 358.55 Million USD | -0.74% |
| 2022 Q2 | 393.47 Million USD | 72.72% |
| 2022 Q1 | 227.81 Million USD | 3.78% |
| 2022 FY | 358.55 Million USD | 63.34% |
| 2022 Q3 | 361.24 Million USD | -8.19% |
| 2021 Q1 | 436.94 Million USD | 2.52% |
| 2021 Q2 | 469.89 Million USD | 7.54% |
| 2021 FY | 219.51 Million USD | -48.49% |
| 2021 Q3 | 469.11 Million USD | -0.17% |
| 2021 Q4 | 219.51 Million USD | -53.21% |
| 2020 Q4 | 426.19 Million USD | 0.88% |
| 2020 Q3 | 422.46 Million USD | -0.77% |
| 2020 Q1 | 408.67 Million USD | -7.63% |
| 2020 Q2 | 425.75 Million USD | 4.18% |
| 2020 FY | 426.19 Million USD | -3.67% |
| 2019 Q2 | 386.97 Million USD | 5.58% |
| 2019 FY | 442.43 Million USD | 23.66% |
| 2019 Q4 | 442.43 Million USD | 5.21% |
| 2019 Q3 | 420.5 Million USD | 8.67% |
| 2019 Q1 | 366.51 Million USD | 2.44% |
| 2018 Q1 | 296.6 Million USD | 7.03% |
| 2018 FY | 357.77 Million USD | 29.1% |
| 2018 Q4 | 357.77 Million USD | 1.93% |
| 2018 Q3 | 350.99 Million USD | 15.47% |
| 2018 Q2 | 303.97 Million USD | 2.48% |
| 2017 Q1 | 257.19 Million USD | 3.42% |
| 2017 Q2 | 257.11 Million USD | -0.03% |
| 2017 FY | 277.13 Million USD | 11.44% |
| 2017 Q4 | 277.13 Million USD | 4.8% |
| 2017 Q3 | 264.43 Million USD | 2.85% |
| 2016 Q3 | 223.74 Million USD | 22.68% |
| 2016 Q4 | 248.68 Million USD | 11.14% |
| 2016 Q1 | 172.19 Million USD | 13.41% |
| 2016 Q2 | 182.37 Million USD | 5.91% |
| 2016 FY | 248.68 Million USD | 63.78% |
| 2015 Q2 | 80.2 Million USD | 35.21% |
| 2015 Q3 | 128.63 Million USD | 60.39% |
| 2015 Q4 | 151.84 Million USD | 18.04% |
| 2015 Q1 | 59.31 Million USD | -9.41% |
| 2015 FY | 151.84 Million USD | 131.88% |
| 2014 Q3 | 68.3 Million USD | -8.77% |
| 2014 Q1 | 65.34 Million USD | -10.15% |
| 2014 Q4 | 65.48 Million USD | -4.13% |
| 2014 Q2 | 74.86 Million USD | 14.57% |
| 2014 FY | 65.48 Million USD | -9.96% |
| 2013 Q2 | 73.27 Million USD | -7.2% |
| 2013 FY | 72.72 Million USD | -41.85% |
| 2013 Q4 | 72.72 Million USD | 3.06% |
| 2013 Q3 | 70.56 Million USD | -3.7% |
| 2013 Q1 | 78.95 Million USD | -36.87% |
| 2012 FY | 125.06 Million USD | 44.38% |
| 2012 Q4 | 125.06 Million USD | 0.0% |
| 2011 FY | 86.62 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 31.953% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -236.739% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 31.258% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -60.396% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -517.554% |
| Imunon, Inc. | 8.53 Million USD | -4877.758% |
| Editas Medicine, Inc. | 150.05 Million USD | -182.977% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 97.936% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 87.887% |
| Myriad Genetics, Inc. | 312.9 Million USD | -35.706% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 58.346% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 12.891% |
| Verastem, Inc. | 71.18 Million USD | -496.508% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.383% |
| Waters Corporation | 3.47 Billion USD | 87.786% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.182% |
| Biogen Inc. | 12.04 Billion USD | 96.475% |
| Nektar Therapeutics | 267.04 Million USD | -59.008% |
| Perrigo Company plc | 6.04 Billion USD | 92.971% |
| Dynavax Technologies Corporation | 375.02 Million USD | -13.226% |
| Illumina, Inc. | 4.36 Billion USD | 90.274% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1107.103% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -116.935% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -65.559% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1038.646% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 77.534% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -415.114% |
| Evolus, Inc. | 209.68 Million USD | -102.504% |
| Adicet Bio, Inc. | 37.12 Million USD | -1043.922% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -955.596% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 94.025% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 35.74% |
| FibroGen, Inc. | 585.72 Million USD | 27.505% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 91.366% |
| OPKO Health, Inc. | 622.47 Million USD | 31.785% |
| Homology Medicines, Inc. | 118.53 Million USD | -258.233% |
| Geron Corporation | 146.12 Million USD | -190.586% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 89.517% |
| Exelixis, Inc. | 678.44 Million USD | 37.412% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -2015.61% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -3287.777% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -69.302% |
| Zoetis Inc. | 9.29 Billion USD | 95.432% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -6.888% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -763.478% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 91.755% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -776.507% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 83.69% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 82.346% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -269.843% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 74.257% |
| Blueprint Medicines Corporation | 918.64 Million USD | 53.777% |
| Insmed Incorporated | 1.66 Billion USD | 74.447% |
| TG Therapeutics, Inc. | 169.08 Million USD | -151.13% |
| Incyte Corporation | 1.59 Billion USD | 73.332% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 64.185% |